Home
VALN
VALN News

Latest Valneva SE (VALN) News on November 17, 2024

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

The Wall Street Journal

2 days ago

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

GlobeNewswire

4 days ago

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

GlobeNewswire

6 days ago

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...

GuruFocus.com

10 days ago

Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

11 days ago

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For

GuruFocus.com

11 days ago

Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For

VALNEVA - Declaration of shares and voting rights: October 31, 2024

GlobeNewswire

12 days ago

VALNEVA - Declaration of shares and voting rights: October 31, 2024

High Growth Tech Stocks in France to Watch October 2024

Simply Wall St.

24 days ago

High Growth Tech Stocks in France to Watch October 2024

Lectra And 2 Other High Growth Tech Stocks In France

Simply Wall St.

25 days ago

Lectra And 2 Other High Growth Tech Stocks In France

Exploring 3 High Growth Tech Stocks In France

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks In France

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

GlobeNewswire

a month ago

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

High Growth Tech Stocks In France Featuring 3 Promising Companies

Simply Wall St.

a month ago

High Growth Tech Stocks In France Featuring 3 Promising Companies

MT Newswires

a month ago

Valneva, LimmaTech Get FDA Fast Track Designation for Shigellosis Vaccine Candidate

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

GlobeNewswire

a month ago

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

High Growth Tech Stocks In France October 2024

Simply Wall St.

a month ago

High Growth Tech Stocks In France October 2024

Valneva Hosts Investor Day in New York City

GlobeNewswire

a month ago

Valneva Hosts Investor Day in New York City

Valneva SE (INRLF) (H1 2024) Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges

GuruFocus.com

a month ago

Valneva SE (INRLF) (H1 2024) Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges

Exclusive Networks And 2 High Growth Tech Stocks In France

Simply Wall St.

a month ago

Exclusive Networks And 2 High Growth Tech Stocks In France

Exploring Three High Growth Tech Stocks in France

Simply Wall St.

a month ago

Exploring Three High Growth Tech Stocks in France

Valneva SE - Declaration of shares and voting rights - September 30, 2024

GlobeNewswire

a month ago

Valneva SE - Declaration of shares and voting rights - September 30, 2024

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

GlobeNewswire

a month ago

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

Valneva eyes teenage label for chikungunya vaccine in Europe and Canada

Pharmaceutical Technology

2 months ago

Valneva eyes teenage label for chikungunya vaccine in Europe and Canada

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

GlobeNewswire

2 months ago

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

GlobeNewswire

2 months ago

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

GlobeNewswire

2 months ago

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

Esker And 2 Other High Growth Tech Stocks In France

Simply Wall St.

2 months ago

Esker And 2 Other High Growth Tech Stocks In France

VALNEVA - Declaration of shares and voting rights: August 31, 2024

GlobeNewswire

2 months ago

VALNEVA - Declaration of shares and voting rights: August 31, 2024

Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study

Benzinga

2 months ago

Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

Zacks

2 months ago

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

Valneva and Pfizer report positive data from trial of Lyme disease vaccine booster

Clinical Trials Arena

2 months ago

Valneva and Pfizer report positive data from trial of Lyme disease vaccine booster

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

GlobeNewswire

2 months ago

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know

Zacks

2 months ago

Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know

High Growth Tech Stocks in France Featuring Lectra and Two More

Simply Wall St.

3 months ago

High Growth Tech Stocks in France Featuring Lectra and Two More

How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%

Zacks

3 months ago

How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

3 months ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

VALNEVA - Declaration of shares and voting rights: July 31, 2024

GlobeNewswire

3 months ago

VALNEVA - Declaration of shares and voting rights: July 31, 2024

Valneva and LimmaTech partner for shigellosis vaccine development

Pharmaceutical Technology

4 months ago

Valneva and LimmaTech partner for shigellosis vaccine development

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

GlobeNewswire

4 months ago

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?

Zacks

4 months ago

Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?

Valneva and CEPI expand deal for chikungunya vaccine trials

Clinical Trials Arena

4 months ago

Valneva and CEPI expand deal for chikungunya vaccine trials

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

GlobeNewswire

4 months ago

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026

Benzinga

4 months ago

Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

GlobeNewswire

4 months ago

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine

Zacks

4 months ago

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine

Declaration of shares and voting rights - Valneva SE - June 30, 2024

GlobeNewswire

4 months ago

Declaration of shares and voting rights - Valneva SE - June 30, 2024

MT Newswires

5 months ago

Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine

Valneva’s chikungunya vaccine gains EC’s market authorisation

Pharmaceutical Technology

5 months ago

Valneva’s chikungunya vaccine gains EC’s market authorisation

Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®

GlobeNewswire

5 months ago

Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

GlobeNewswire

5 months ago

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval

Zacks

5 months ago

Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval

MT Newswires

5 months ago

Valneva's Chikungunya Vaccine Receives Health Canada's Approval

Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

GlobeNewswire

5 months ago

Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

GlobeNewswire

5 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

VALNEVA - Declaration of shares and voting rights: May 31, 2024

GlobeNewswire

5 months ago

VALNEVA - Declaration of shares and voting rights: May 31, 2024

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

GlobeNewswire

5 months ago

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

GlobeNewswire

5 months ago

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

MT Newswires

6 months ago

Valneva's Chikungunya Vaccine Gains Support From EU Regulator Committee

Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

GlobeNewswire

6 months ago

Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

GlobeNewswire

6 months ago

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine

GlobeNewswire

6 months ago

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

6 months ago

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

GlobeNewswire

6 months ago

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

Declaration of voting rights - Valneva SE, March 2024

GlobeNewswire

7 months ago

Declaration of voting rights - Valneva SE, March 2024

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

GlobeNewswire

8 months ago

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

GlobeNewswire

8 months ago

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

GlobeNewswire

8 months ago

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

GlobeNewswire

8 months ago

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

GlobeNewswire

8 months ago

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

VALNEVA Declaration of shares and voting rights - February 29, 2024

GlobeNewswire

8 months ago

VALNEVA Declaration of shares and voting rights - February 29, 2024

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

GlobeNewswire

8 months ago

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

GlobeNewswire

9 months ago

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

GlobeNewswire

9 months ago

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

VALNEVA: Declaration of shares and voting rights - January 31, 2024

GlobeNewswire

9 months ago

VALNEVA: Declaration of shares and voting rights - January 31, 2024

Valneva sells regulatory ‘fast pass’ for $103M

BioPharma Dive

9 months ago

Valneva sells regulatory ‘fast pass’ for $103M

Valneva Announces Sale of Priority Review Voucher for $103 Million

GlobeNewswire

9 months ago

Valneva Announces Sale of Priority Review Voucher for $103 Million

Deluxe Reports Fourth Quarter and Full Year 2023 Results; Affirms Full Year 2024 Outlook

Business Wire

10 months ago

Deluxe Reports Fourth Quarter and Full Year 2023 Results; Affirms Full Year 2024 Outlook

Byline Bancorp (NYSE:BY) Has Affirmed Its Dividend Of $0.09

Simply Wall St.

10 months ago

Byline Bancorp (NYSE:BY) Has Affirmed Its Dividend Of $0.09

12 Most Promising Green Stocks According to Analysts

Insider Monkey

10 months ago

12 Most Promising Green Stocks According to Analysts

With 85% institutional ownership, REX American Resources Corporation (NYSE:REX) is a favorite amongst the big guns

Simply Wall St.

10 months ago

With 85% institutional ownership, REX American Resources Corporation (NYSE:REX) is a favorite amongst the big guns

Preferred Bank (NASDAQ:PFBC) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

Preferred Bank (NASDAQ:PFBC) Q4 2023 Earnings Call Transcript

4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 Shares

GuruFocus.com

10 months ago

4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 Shares

Interface Circular Approach Recognized by The World Economic Forum and McKinsey as a Circularity Lighthouse in the Built Environment

Business Wire

10 months ago

Interface Circular Approach Recognized by The World Economic Forum and McKinsey as a Circularity Lighthouse in the Built Environment

Lawmakers press Steward Health Care over reports of ‘grave financial distress’

Healthcare Dive

10 months ago

Lawmakers press Steward Health Care over reports of ‘grave financial distress’

Zacks Industry Outlook Highlights American Water Works, California Water Service, SJW Group and Consolidated Water

Zacks

10 months ago

Zacks Industry Outlook Highlights American Water Works, California Water Service, SJW Group and Consolidated Water

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

Zacks

10 months ago

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

Mercury Introduces Direct RF System-On-Module Powered by Intel Agilex FPGA

GlobeNewswire

10 months ago

Mercury Introduces Direct RF System-On-Module Powered by Intel Agilex FPGA

Personal Care Stocks Q3 Recap: Benchmarking Herbalife (NYSE:HLF)

StockStory

10 months ago

Personal Care Stocks Q3 Recap: Benchmarking Herbalife (NYSE:HLF)

Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares

GuruFocus.com

10 months ago

Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares

Does ACM Research, Inc. (ACMR) Have the Potential to Rally 28.31% as Wall Street Analysts Expect?

Zacks

10 months ago

Does ACM Research, Inc. (ACMR) Have the Potential to Rally 28.31% as Wall Street Analysts Expect?

Kornit Digital (NASDAQ:KRNT) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

10 months ago

Kornit Digital (NASDAQ:KRNT) Is In A Good Position To Deliver On Growth Plans

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

GlobeNewswire

10 months ago

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

Is Now The Time To Look At Buying Canadian Solar Inc. (NASDAQ:CSIQ)?

Simply Wall St.

10 months ago

Is Now The Time To Look At Buying Canadian Solar Inc. (NASDAQ:CSIQ)?

Is Viad Corp (NYSE:VVI) Potentially Undervalued?

Simply Wall St.

10 months ago

Is Viad Corp (NYSE:VVI) Potentially Undervalued?

Business Wire

10 months ago

Pagaya Announces Strategic Actions to Enhance Marketability of its Stock, Strong Financial Outperformance in 4Q23 and FY23

Kosmos Energy Stock (NYSE:KOS): Bearish Options Traders are Barking Up the Wrong Tree

TipRanks

10 months ago

Kosmos Energy Stock (NYSE:KOS): Bearish Options Traders are Barking Up the Wrong Tree

Dish Launches Debt Swap After Controversial Asset Transfer

Bloomberg

10 months ago

Dish Launches Debt Swap After Controversial Asset Transfer

While insiders own 36% of EHang Holdings Limited (NASDAQ:EH), individual investors are its largest shareholders with 46% ownership

Simply Wall St.

10 months ago

While insiders own 36% of EHang Holdings Limited (NASDAQ:EH), individual investors are its largest shareholders with 46% ownership

PR Newswire

10 months ago

NEW YEAR, NEW PIZOOKIE®: BJ's RESTAURANT & BREWHOUSE® INTRODUCES THE BRAND-NEW CINNAMON ROLL PIZOOKIE®

abrdn U.S. Closed End Funds Announce Distribution Payment Details

ACCESSWIRE

10 months ago

abrdn U.S. Closed End Funds Announce Distribution Payment Details

Share on Social Networks: